Trials / Not Yet Recruiting
Not Yet RecruitingNCT04158856
Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer
Adjuvant Dual Anti-HER2 Therapy in Patients With Tumors < 8mm, Node-negative, HER2-positive Breast Cancer :a Single-group Arm, Open-label, Prospective, Phase 2 Study
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- xuexin he · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This phase II trial aims to study the efficacy and safety of adjuvant Pyrotinib plus trastuzumab in patients with tumors \<8mm, node-negative, HER2-positive breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pyrotinib | 400mg po every day |
| DRUG | Trastuzumab | Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2023-05-31
- Completion
- 2030-05-31
- First posted
- 2019-11-12
- Last updated
- 2019-11-12
Source: ClinicalTrials.gov record NCT04158856. Inclusion in this directory is not an endorsement.